Ascendis has big pharma bidders; Lexicon buys rights to Symphony Icon;

 @FierceBiotech: Charles River, WuXi call off $1.6B deal. Report | Follow @FierceBiotech

 @JohnCFierce: Isis says liver enzymes spike when you lower cholesterol; with statins or mipomersen. Could that fly at FDA? I doubt it. | Follow @JohnCFierce

> Quoting sources, Bloomberg reported on Friday that Novo Nordisk, Eli Lilly and Novartis are among the bidders for Denmark's Ascendis Pharma. Sources say the bids are in the $400 million range. Story

> Lexicon Pharmaceuticals has struck a deal to acquire all the rights to Symphony Icon Holdings, thereby regaining the rights to drug programs included under an earlier collaboration pact. The new deal covers LX1031, LX1032 and LX1033. Report 

> San Diego-based Conatus acquired Pfizer's Idun Pharmaceuticals for an undisclosed sum. The deal will help Conatus pursue new work in liver disease and oncology. Story

> INEOS Group has struck a binding agreement for the sale of its Global Films business to Bilcare, a leading provider of research led packaging to the global pharmaceuticals industry, for approximately €100 million. Release

> Sagent Pharmaceuticals has won two FDA approvals for sumatriptan succinate injection and rocuronium bromide injection. Release

> Merz Pharmaceuticals announced that the FDA has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. Release

And Finally... Researchers have discovered a novel mechanism in salmonella that affects its virulence and its susceptibility to antibiotics by changing its production of proteins in a previously unheard of manner. Article

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.